696640-67-2

Upstream product

• 227177-02-8 (1S,5R,6S,7R,8S,9R)-6,8,9-Tris-benzyloxy-7-(4-methoxy-benzyloxy)-3-methyl-2,4-dioxa-bicyclo[3.3.1]nonane 
• 227177-03-9 1D-2,4,6-tri-O-benzyl-1-O-(4'-methoxybenzyl)-myo-inositol 
• 227177-05-1 (1R,5S,6S,7R,8S,9R)-6,8,9-Tris-benzyloxy-3-methyl-2,4-dioxa-bicyclo[3.3.1]nonan-7-ol 
• 114847-11-9 meso-2,4,6-tri-O-benzyl-D-myo-inositol-1,3,5-O-orthoformate 
• 98510-20-4 myo-Inositol orthoformate 
• 100-39-0 benzyl bromide 
• 163878-18-0 (+)-(1S,2R,4R,6R)-2,4-Bis(benzyloxy)-1,6-epoxycyclohexane 
• 100-51-6 benzyl alcohol 

Relevant academic research and scientific papers

Synthesis of 1-O-(2-oxo-benzo-1,3,2-dioxaphosphaocan-2-yl)-myo-inositol and 3,5-dideoxy-1-O-(2-oxo-benzo-1,3,2-dioxaphosphaocan-2-yl)-myo-inositol as prodrugs of inositolmonophosphatase ligands

1-O-(2-oxo-benzo-1,3,2-dioxaphosphaocan-2-yl)-myo-inositol and 3,5- dideoxy-1-O-(2-oxo-benzo-1,3,2-dioxaphosphaocan-2-yl)-myo-inositol were prepared by selective modifications of myo-inositol. Phosphorylation used the phosphite method by means of the 2(N,N-di-isopropylamino)-benzo-1,3,2- dioxaphosphaocane.

Removal of the phosphate group in mechanism-based inhibitors of inositol monophosphatase leads to unusual inhibitory activity.

Inositol monophosphatase is widely held to be the therapeutic target for inhibition by lithium ion in the treatment of bipolar disorder. In a continued effort to improve the bioavailability of alternative inhibitors, we have designed and tested two new se